{
  "main_header": {
    "sid": 1232279,
    "name": "Bionano Genomics, Inc.",
    "stock_name": "Bionano Genomics, Inc.",
    "full_name": "Bionano Genomics, Inc.",
    "name_url": "stocks-analysis/bionano-genomics-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "1.70",
    "chg": 0.02,
    "chgp": "1.19%",
    "dir": 1,
    "prev_price": "1.68",
    "mcapval": "19.94",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2320,
    "indexname": "S&P 500",
    "isin": "US09075F3055",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "447.27 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/bionano-genomics-inc-1232279-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Bionano Genomics, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-bionano-genomics-inc-technically-bullish-or-bearish-3546772",
        "imagepath": "",
        "date": "2025-09-20 19:40:12",
        "description": "As of 12 September 2025, the technical trend for Bionano Genomics, Inc. has changed from mildly bullish to sideways. The current technical stance is neutral, with mixed signals across various indicators. The MACD shows a mildly bullish stance on both weekly and monthly time frames, while the RSI indicates a bullish monthly signal but no signal on the weekly. However, Bollinger Bands and moving averages are bearish on the weekly and daily time frames, and Dow Theory is bearish on the weekly. Additionally, the stock has significantly underperformed compared to the S&P 500, with a year-to-date return of -89.66% versus the S&P 500's 12.22%...."
      },
      {
        "title": "Bionano Genomics Hits 52-Week Low at $1.50 Amidst Major Decline",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bionano-genomics-hits-52-week-low-at-150-amidst-major-decline-3525923",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/9/BionanoGenomics_priceRelatedfactors_3525923.png",
        "date": "2025-09-17 15:17:55",
        "description": "Bionano Genomics, Inc. has reached a new 52-week low, reflecting a significant decline in its stock price over the past year. With a market capitalization of approximately USD 20 million, the company faces financial challenges, including negative return on equity and a low price-to-book ratio, despite some operational improvements."
      }
    ],
    "total": 6,
    "sid": "1232279",
    "stock_news_url": "https://www.marketsmojo.com/news/bionano-genomics-inc-1232279"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Is Bionano Genomics, Inc. technically bullish or bearish?

2025-09-20 19:40:12

As of 12 September 2025, the technical trend for Bionano Genomics, Inc. has changed from mildly bullish to sideways. The current technical stance is neutral, with mixed signals across various indicators. The MACD shows a mildly bullish stance on both weekly and monthly time frames, while the RSI indicates a bullish monthly signal but no signal on the weekly. However, Bollinger Bands and moving averages are bearish on the weekly and daily time frames, and Dow Theory is bearish on the weekly. Additionally, the stock has significantly underperformed compared to the S&P 500, with a year-to-date return of -89.66% versus the S&P 500's 12.22%....

Read More

Bionano Genomics Hits 52-Week Low at $1.50 Amidst Major Decline

2025-09-17 15:17:55

Bionano Genomics, Inc. has reached a new 52-week low, reflecting a significant decline in its stock price over the past year. With a market capitalization of approximately USD 20 million, the company faces financial challenges, including negative return on equity and a low price-to-book ratio, despite some operational improvements.

Read More

View All News